N/A N=25 A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)
Cataract
Primary: Mean Binocular Defocus VA at Month 3 — 0.78; 0.59; 0.65; 0.45 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=103 Ultrasound Guided Supraclavicular Nerve Block
Local Anesthetic
Primary: Duration of Analgesia. — 7.5; 10 minute — p=0.14
N/A N=70 A Randomized Comparison of Intraoperative Warming With the LMA PerfecTemp and Forced-air
Warming Systems During Surgery
Primary: Time Weighted Average Core Temperature — 36.11; 36.02 Degrees C
Phase 3 N=79 Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
COPD
Primary: Area Under the Curve for Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) From 0 to 12 Hours (AUC0-12) on Day 8 — 1.538; 1.516 Liter
Phase 2 N=26 Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action
Interstitial Cystitis
Primary: Symptom Improvement of Interstitial Cystitis — 9 Participants
Phase 3 N=215 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24) — 42.9; 45.5 units on a scale
Phase 3 N=10 Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders
Bipolar Disorder · Substance Use Disorder
Primary: Change in Hamilton Rating Scale of Depression (HAMD) From Baseline to Week 8 (Exit) — 17.5; 9 HAMD scale units — p=.012
Phase 3 N=25 Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Bipolar II Disorder
Primary: Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10 — 4; 3; 10; 8 participants
Phase 3 N=80 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
COPD
Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24 — 0.192; 0.112; -0.072 Liters
Phase 2 N=303 Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival — 15.0…
Phase 3 N=64 Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR
Attention Deficit Hyperactivity Disorder
Primary: Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks. — 2249; 2304; 2319; 2325 HHMM.SS
Phase 4 N=15 Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.
Metabolic Syndrome
Primary: Insulin-stimulated AKT Phosphorylation — 0.065; -0.457 change in ratio
Phase 3 N=43 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
COPD
Primary: FEV1 AUC0-24 on Day 29 — 0.166; -0.083 Liters
Phase 4 N=55 Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
Heartburn
Primary: Number of Participants With Relief of 24 Hour Heartburn and Without Relief of 24 Hour Heartburn — 7; 10; 0; 9 participants
Phase 2 N=144 Effectiveness of Bupropion for Treating Nicotine Dependence in Young People
Tobacco Use Cessation · Tobacco Use Disorder
Primary: Smoking Behavior — 6.4; 8.9 cigarettes/day in the previous week